-
1
-
-
79952444246
-
Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association
-
Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-944.
-
(2011)
Circulation
, vol.123
, Issue.8
, pp. 933-944
-
-
Heidenreich, P.A.1
Trogdon, J.G.2
Khavjou, O.A.3
-
2
-
-
0035897696
-
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
-
(2001)
JAMA
, vol.285
, Issue.19
, pp. 2486-2497
-
-
-
3
-
-
33744982042
-
-
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute
-
Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.
-
(2006)
Circulation
, vol.113
, Issue.19
, pp. 2363-2372
-
-
Smith Jr., S.C.1
Allen, J.2
Blair, S.N.3
-
4
-
-
0037031061
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial
-
Heart Protection Study Collaborative Group
-
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7-22.
-
(2002)
Lancet
, vol.360
, Issue.9326
, pp. 7-22
-
-
-
5
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
-
(2008)
N Engl J Med
, vol.359
, Issue.21
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
-
6
-
-
0029004377
-
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
-
Scandinavian Simvastatin Survival Study Group
-
Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345(8960):1274-1275.
-
(1995)
Lancet
, vol.345
, Issue.8960
, pp. 1274-1275
-
-
-
7
-
-
2942720515
-
Beneficial cardiovascular pleiotropic effects of statins
-
Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39-III43.
-
(2004)
Circulation
, vol.109
, Issue.23 SUPPL. 1
-
-
Davignon, J.1
-
8
-
-
34748887666
-
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
-
for Treating to New Targets Investigators
-
Barter P, Gotto AM, LaRosa JC; for Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-1310.
-
(2007)
N Engl J Med
, vol.357
, Issue.13
, pp. 1301-1310
-
-
Barter, P.1
Gotto, A.M.2
Larosa, J.C.3
-
9
-
-
0017384270
-
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
-
Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707-714.
-
(1977)
Am J Med
, vol.62
, Issue.5
, pp. 707-714
-
-
Gordon, T.1
Castelli, W.P.2
Hjortland, M.C.3
Kannel, W.B.4
Dawber, T.R.5
-
10
-
-
0029759109
-
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport
-
Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124 Suppl:S11-S20.
-
(1996)
Atherosclerosis
, vol.124
, Issue.SUPPL.
-
-
Assmann, G.1
Schulte, H.2
von Eckardstein, A.3
Huang, Y.4
-
11
-
-
0018719409
-
High density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli Ischemic Heart Disease Study
-
Goldbourt U, Medalie JH. High density lipoprotein cholesterol and incidence of coronary heart disease - the Israeli Ischemic Heart Disease Study. Am J Epidemiol. 1979;109(3):296-308.
-
(1979)
Am J Epidemiol
, vol.109
, Issue.3
, pp. 296-308
-
-
Goldbourt, U.1
Medalie, J.H.2
-
12
-
-
0017614773
-
The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: A prospective case-control study
-
Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1(8019):965-968.
-
(1977)
Lancet
, vol.1
, Issue.8019
, pp. 965-968
-
-
Miller, N.E.1
Thelle, D.S.2
Forde, O.H.3
Mjos, O.D.4
-
13
-
-
0024501678
-
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
-
Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8-15.
-
(1989)
Circulation
, vol.79
, Issue.1
, pp. 8-15
-
-
Gordon, D.J.1
Probstfield, J.L.2
Garrison, R.J.3
-
14
-
-
33645308302
-
Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport
-
Duffy D, Rader DJ. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation. 2006;113:1140-1150.
-
(2006)
Circulation
, vol.113
, pp. 1140-1150
-
-
Duffy, D.1
Rader, D.J.2
-
15
-
-
34147223018
-
Emerging HDL-based therapies for atherothrombotic vascular disease
-
Shah PK. Emerging HDL-based therapies for atherothrombotic vascular disease. Curr Treat Options Cardiovasc Med. 2007;9(1):60-70.
-
(2007)
Curr Treat Options Cardiovasc Med
, vol.9
, Issue.1
, pp. 60-70
-
-
Shah, P.K.1
-
16
-
-
12144287356
-
Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib
-
Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24(3):490-497.
-
(2004)
Arterioscler Thromb Vasc Biol
, vol.24
, Issue.3
, pp. 490-497
-
-
Clark, R.W.1
Sutfin, T.A.2
Ruggeri, R.B.3
-
17
-
-
1842815777
-
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
-
Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
-
(2004)
N Engl J Med
, vol.350
, pp. 1505-1515
-
-
Brousseau, M.E.1
Schaefer, E.J.2
Wolfe, M.L.3
-
18
-
-
33750477286
-
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels
-
Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774-1781.
-
(2006)
J Am Coll Cardiol
, vol.48
, pp. 1774-1781
-
-
Davidson, M.H.1
McKenney, J.M.2
Shear, C.L.3
Revkin, J.H.4
-
19
-
-
33750447972
-
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin
-
McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006;48:1782-1790.
-
(2006)
J Am Coll Cardiol
, vol.48
, pp. 1782-1790
-
-
McKenney, J.M.1
Davidson, M.H.2
Shear, C.L.3
Revkin, J.H.4
-
20
-
-
36348975228
-
Effects of torcetrapib in patients at high risk for coronary events
-
Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
-
(2007)
N Engl J Med
, vol.357
, pp. 2109-2122
-
-
Barter, P.J.1
Caulfield, M.2
Eriksson, M.3
-
21
-
-
34047106220
-
Effect of torcetrapib on the progression of coronary atherosclerosis
-
Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316.
-
(2007)
N Engl J Med
, vol.356
, pp. 1304-1316
-
-
Nissen, S.E.1
Tardif, J.C.2
Nicholls, S.J.3
-
22
-
-
34247241088
-
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
-
Kastelein J, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
-
(2007)
N Engl J Med
, vol.356
, pp. 1620-1630
-
-
Kastelein, J.1
van Leuven, S.I.2
Burgess, L.3
-
23
-
-
34447265547
-
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial
-
Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582):153-160.
-
(2007)
Lancet
, vol.370
, Issue.9582
, pp. 153-160
-
-
Bots, M.L.1
Visseren, F.L.2
Evans, G.W.3
-
24
-
-
17444372760
-
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia
-
Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95:1085-1088.
-
(2005)
Am J Cardiol
, vol.95
, pp. 1085-1088
-
-
Kuivenhoven, J.A.1
de Grooth, G.J.2
Kawamura, H.3
-
25
-
-
36549078679
-
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomized placebo-controlled phase I studies
-
Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370(9603):1907-1914.
-
(2007)
Lancet
, vol.370
, Issue.9603
, pp. 1907-1914
-
-
Krishna, R.1
Anderson, M.S.2
Bergman, A.J.3
-
26
-
-
48149106322
-
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
-
Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465-1473.
-
(2008)
Br J Pharmacol
, vol.154
, pp. 1465-1473
-
-
Forrest, M.J.1
Bloomfield, D.2
Briscoe, R.J.3
-
27
-
-
71749117374
-
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors
-
Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol. 2009;104 Suppl:32E-38E.
-
(2009)
Am J Cardiol
, vol.104
, Issue.SUPPL.
-
-
Vergeer, M.1
Stroes, E.S.2
-
28
-
-
84875396032
-
A randomized, double-blind, placebo-controlled study assessing the effect of ro4607381 on cardiovascular mortality and morbidity in clinically stable patients with a recent acute coronary syndrome
-
Internet, Bethesda, MD: National Library of Medicine, cited May 28, 2012, Available, NLM Identifier: NCT00658515
-
Hoffmann-La Roche. A randomized, double-blind, placebo-controlled study assessing the effect of ro4607381 on cardiovascular mortality and morbidity in clinically stable patients with a recent acute coronary syndrome. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000. [cited May 28, 2012]. Available from: http://clinicaltrials.gov/show/NCT00658515. NLM Identifier: NCT00658515.
-
(2000)
ClinicalTrials.gov
-
-
Hoffmann-La, R.1
-
29
-
-
77956513064
-
Biochemical characterization of cholesteryl ester transfer protein inhibitors
-
Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51(9):2739-2752.
-
(2010)
J Lipid Res
, vol.51
, Issue.9
, pp. 2739-2752
-
-
Ranalletta, M.1
Bierilo, K.K.2
Chen, Y.3
-
31
-
-
31644445200
-
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
-
Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol. 2006;47(3):492-499.
-
(2006)
J Am Coll Cardiol
, vol.47
, Issue.3
, pp. 492-499
-
-
Barter, P.J.1
Kastelein, J.J.2
-
32
-
-
33746766313
-
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
-
Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006;111(3):893-908.
-
(2006)
Pharmacol Ther
, vol.111
, Issue.3
, pp. 893-908
-
-
Chapman, M.J.1
-
33
-
-
1942428112
-
Reverse cholesterol transport: High-density lipoprotein's magnificent mile
-
Toth PP. Reverse cholesterol transport: high-density lipoprotein's magnificent mile. Curr Atheroscler Rep. 2003;5:386-393.
-
(2003)
Curr Atheroscler Rep
, vol.5
, pp. 386-393
-
-
Toth, P.P.1
-
34
-
-
79954515931
-
Cholesteryl ester transfer protein: The controversial relation to atherosclerosis and emerging new biological roles
-
Oliveira HC, de Faria EC. Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life. 2011;63(4):248-257.
-
(2011)
IUBMB Life
, vol.63
, Issue.4
, pp. 248-257
-
-
Oliveira, H.C.1
de Faria, E.C.2
-
35
-
-
33846381019
-
Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease
-
Shah PK. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur Heart J. 2007;28(1):5-12.
-
(2007)
Eur Heart J
, vol.28
, Issue.1
, pp. 5-12
-
-
Shah, P.K.1
-
36
-
-
0027502421
-
Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B
-
Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993;94(4):350-356.
-
(1993)
Am J Med
, vol.94
, Issue.4
, pp. 350-356
-
-
Chait, A.1
Brazg, R.L.2
Tribble, D.L.3
Krauss, R.M.4
-
37
-
-
0027938951
-
Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk
-
Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994;5(5):339-349.
-
(1994)
Curr Opin Lipidol
, vol.5
, Issue.5
, pp. 339-349
-
-
Krauss, R.M.1
-
38
-
-
0028857779
-
Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase
-
Hirano K, Yamashita S, Kuga Y, et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol. 1995;15:1849-1856.
-
(1995)
Arterioscler Thromb Vasc Biol
, vol.15
, pp. 1849-1856
-
-
Hirano, K.1
Yamashita, S.2
Kuga, Y.3
-
39
-
-
0029948968
-
Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels
-
Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97(12):2917-2923.
-
(1996)
J Clin Invest
, vol.97
, Issue.12
, pp. 2917-2923
-
-
Zhong, S.1
Sharp, D.S.2
Grove, J.S.3
-
40
-
-
67649367650
-
Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study
-
Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet. 2009;2(1):26-33.
-
(2009)
Circ Cardiovasc Genet
, vol.2
, Issue.1
, pp. 26-33
-
-
Ridker, P.M.1
Paré, G.2
Parker, A.N.3
Zee, R.Y.4
Miletich, J.P.5
Chasman, D.I.6
-
41
-
-
2142763867
-
Prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly
-
Curb JD, Abbott RD, Rodriguez BL, et al. Prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004;45(5):948-953.
-
(2004)
J Lipid Res
, vol.45
, Issue.5
, pp. 948-953
-
-
Curb, J.D.1
Abbott, R.D.2
Rodriguez, B.L.3
-
42
-
-
76749125435
-
Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys
-
Tan EY, Hartmann G, Chen Q, et al. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys. Drug Metab Dispos. 2010;38:459-473.
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 459-473
-
-
Tan, E.Y.1
Hartmann, G.2
Chen, Q.3
-
43
-
-
70350788822
-
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
-
Krishna R, Garg A, Panebianco D, et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;68:535-545.
-
(2009)
Br J Clin Pharmacol
, vol.68
, pp. 535-545
-
-
Krishna, R.1
Garg, A.2
Panebianco, D.3
-
44
-
-
56549117314
-
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
-
Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther. 2008;84:679-683.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 679-683
-
-
Krishna, R.1
Bergman, A.J.2
Jin, B.3
-
45
-
-
76749149144
-
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans
-
Kumar S, Tan EY, Hartmann G, et al. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos. 2010;38:474-483.
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 474-483
-
-
Kumar, S.1
Tan, E.Y.2
Hartmann, G.3
-
46
-
-
80053620685
-
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia
-
Dansky HM, Bloomfield D, Gibbons P, et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. Am Heart J. 2011;162(4):708-716.
-
(2011)
Am Heart J
, vol.162
, Issue.4
, pp. 708-716
-
-
Dansky, H.M.1
Bloomfield, D.2
Gibbons, P.3
-
47
-
-
58149202372
-
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers
-
Krishna R, Bergman AJ, Jin B, et al. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol. 2009;49(1):80-87.
-
(2009)
J Clin Pharmacol
, vol.49
, Issue.1
, pp. 80-87
-
-
Krishna, R.1
Bergman, A.J.2
Jin, B.3
-
48
-
-
65349191226
-
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein(CETP) inhibitor, in healthy subjects
-
Krishna R, Garg A, Jin B, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein(CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2009;67:520-526.
-
(2009)
Br J Clin Pharmacol
, vol.67
, pp. 520-526
-
-
Krishna, R.1
Garg, A.2
Jin, B.3
-
49
-
-
84862126536
-
Lack of meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
-
Krishna R, Stypinski D, Ali M, et al. Lack of meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2012;74(1):116-124.
-
(2012)
Br J Clin Pharmacol
, vol.74
, Issue.1
, pp. 116-124
-
-
Krishna, R.1
Stypinski, D.2
Ali, M.3
-
50
-
-
82155162318
-
Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects
-
Krishna R, Stypinski D, Ali M, et al. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects. Biopharm Drug Dispos. 2011;32(9):525-529.
-
(2011)
Biopharm Drug Dispos
, vol.32
, Issue.9
, pp. 525-529
-
-
Krishna, R.1
Stypinski, D.2
Ali, M.3
-
51
-
-
33644775588
-
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
-
Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47(3):537-552.
-
(2006)
J Lipid Res
, vol.47
, Issue.3
, pp. 537-552
-
-
Clark, R.W.1
Ruggeri, R.B.2
Cunningham, D.3
Bamberger, M.J.4
-
52
-
-
58649091088
-
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
-
Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352-360.
-
(2009)
Am Heart J
, vol.157
, pp. 352-360
-
-
Bloomfield, D.1
Carlson, G.L.2
Sapre, A.3
-
53
-
-
84863232685
-
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib
-
Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53(3):540-547.
-
(2012)
J Lipid Res
, vol.53
, Issue.3
, pp. 540-547
-
-
Krauss, R.M.1
Wojnooski, K.2
Orr, J.3
-
54
-
-
79957463739
-
Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor
-
Krishna R, Bergman AJ, Green M, Dockendorf MF, Wagner JA, Dykstra K. Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor. AAPS J. 2011;13(2):179-190.
-
(2011)
AAPS J
, vol.13
, Issue.2
, pp. 179-190
-
-
Krishna, R.1
Bergman, A.J.2
Green, M.3
Dockendorf, M.F.4
Wagner, J.A.5
Dykstra, K.6
-
55
-
-
70349213361
-
Design of the DEFINE trial: Determining the efficacy and tolerability of CETP inhibition with anacetrapib
-
Cannon CP, Dansky HM, Davidson M, et al. Design of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapib. Am Heart J. 2009;158(4):513-519.
-
(2009)
Am Heart J
, vol.158
, Issue.4
, pp. 513-519
-
-
Cannon, C.P.1
Dansky, H.M.2
Davidson, M.3
-
56
-
-
78549235583
-
Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease
-
Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406-2415.
-
(2010)
N Engl J Med
, vol.363
, Issue.25
, pp. 2406-2415
-
-
Cannon, C.P.1
Shah, S.2
Dansky, H.M.3
-
57
-
-
84875400841
-
REVEAL: Randomized EValuation of the Effects of Anacetrapib through Lipid-modification. A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease
-
Internet, Bethesda, MD: National Library of Medicine, cited May 28, 2012, Available from:, NLM Identifier: NCT01252953
-
Landray M, Bowman L. REVEAL: Randomized EValuation of the Effects of Anacetrapib through Lipid-modification. A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine; 2000 [cited May 28, 2012]. Available from: http://clinicaltrials.gov/show/NCT01252953. NLM Identifier: NCT01252953.
-
(2000)
ClinicalTrials.gov
-
-
Landray, M.1
Bowman, L.2
-
58
-
-
84865215836
-
Niacin: Another look at an underutilized lipid-lowering medication
-
February 21, Epub ahead of print
-
Creider JC, Hegele RA, Joy TR. Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol. February 21, 2012. [Epub ahead of print.]
-
(2012)
Nat Rev Endocrinol
-
-
Creider, J.C.1
Hegele, R.A.2
Joy, T.R.3
-
59
-
-
84860303700
-
Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells
-
Zhang LH, Kamanna VS, Ganji SH, Xiong XM, Kashyap ML. Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells. J Lipid Res. 2012;53(5):941-950.
-
(2012)
J Lipid Res
, vol.53
, Issue.5
, pp. 941-950
-
-
Zhang, L.H.1
Kamanna, V.S.2
Ganji, S.H.3
Xiong, X.M.4
Kashyap, M.L.5
-
60
-
-
55449114841
-
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden. CETP mice
-
van der Hoorn JW, de Haan W, Berbée JF, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden. CETP mice. Arterioscler Thromb Vasc Biol. 2008;28(11):2016-2022.
-
(2008)
Arterioscler Thromb Vasc Biol
, vol.28
, Issue.11
, pp. 2016-2022
-
-
van der Hoorn, J.W.1
de Haan, W.2
Berbée, J.F.3
-
61
-
-
84875398178
-
-
Abbott Laboratories, [package insert], North Chicago, IL: Abbott Laboratories
-
Abbott Laboratories. NIASPAN [package insert]. North Chicago, IL: Abbott Laboratories; 2010.
-
(2010)
NIASPAN
-
-
-
63
-
-
77952397461
-
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
-
Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353-361.
-
(2010)
Atherosclerosis
, vol.210
, Issue.2
, pp. 353-361
-
-
Bruckert, E.1
Labreuche, J.2
Amarenco, P.3
-
64
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
for AIM-HIGH Investigators
-
Boden WE, Probstfield JL, Anderson T, et al; for AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267.
-
(2011)
N Engl J Med
, vol.365
, Issue.24
, pp. 2255-2267
-
-
Boden, W.E.1
Probstfield, J.L.2
Anderson, T.3
-
65
-
-
77952955394
-
Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk
-
Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314-345.
-
(2010)
Pharmacol Ther
, vol.126
, Issue.3
, pp. 314-345
-
-
Chapman, M.J.1
Redfern, J.S.2
McGovern, M.E.3
Giral, P.4
-
66
-
-
80053185929
-
Fenofibrate: A review of its use in dyslipidaemia
-
McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs. 2011;71(14):1917-1946.
-
(2011)
Drugs
, vol.71
, Issue.14
, pp. 1917-1946
-
-
McKeage, K.1
Keating, G.M.2
-
67
-
-
0142181135
-
Possible differences between fibrates in pharmacokinetic interactions with statins
-
Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med. 2003; 163(19):2394-2395.
-
(2003)
Arch Intern Med
, vol.163
, Issue.19
, pp. 2394-2395
-
-
Ballantyne, C.M.1
Davidson, M.H.2
-
68
-
-
1542314891
-
Current overview of statin-induced myopathy
-
Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116(6):408-416.
-
(2004)
Am J Med
, vol.116
, Issue.6
, pp. 408-416
-
-
Rosenson, R.S.1
-
69
-
-
59049086841
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia
-
Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103(4):515-522.
-
(2009)
Am J Cardiol
, vol.103
, Issue.4
, pp. 515-522
-
-
Goldberg, A.C.1
Bays, H.E.2
Ballantyne, C.M.3
-
70
-
-
80051665684
-
The use of fibric acid derivatives in cardiovascular prevention
-
Khoury N, Goldberg AC. The use of fibric acid derivatives in cardiovascular prevention. Curr Treat Options Cardiovasc Med. 2011;13(4): 335-342.
-
(2011)
Curr Treat Options Cardiovasc Med
, vol.13
, Issue.4
, pp. 335-342
-
-
Khoury, N.1
Goldberg, A.C.2
-
71
-
-
0033527030
-
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
-
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
-
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410-418.
-
(1999)
N Engl J Med
, vol.341
, Issue.6
, pp. 410-418
-
-
Rubins, H.B.1
Robins, S.J.2
Collins, D.3
-
72
-
-
0035962077
-
Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial
-
VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial
-
Robins SJ, Collins D, Wittes JT, et al; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285(12):1585-1591.
-
(2001)
JAMA
, vol.285
, Issue.12
, pp. 1585-1591
-
-
Robins, S.J.1
Collins, D.2
Wittes, J.T.3
-
73
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
for ACCORD Study Group
-
Ginsberg HN, Elam MB, Lovato LC, et al; for ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
-
(2010)
N Engl J Med
, vol.362
, Issue.17
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
-
74
-
-
84865232107
-
Relative efficacy of antilipemic agents in non-high-density lipoprotein cholesterol reduction
-
May 2, Epub ahead of print
-
Santee J, Lindsey C, Pace H. Relative efficacy of antilipemic agents in non-high-density lipoprotein cholesterol reduction. J Pharm Pract. May 2, 2012. [Epub ahead of print.]
-
(2012)
J Pharm Pract
-
-
Santee, J.1
Lindsey, C.2
Pace, H.3
-
75
-
-
0033984436
-
Current perspectives on statins
-
Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207-213.
-
(2000)
Circulation
, vol.101
, Issue.2
, pp. 207-213
-
-
Maron, D.J.1
Fazio, S.2
Linton, M.F.3
|